Valutazione economica di erlotinib, docetaxel e pemetrexed nel trattamento di seconda linea del carcinoma polmonare non a piccole cellule

Translated title of the contribution: Economic evaluation of erlotinib, docetaxel and pemetrexed as second line therapy in non-small cell lung cancer

Stefano Capri, A. Morabito, G. Carillio, F. Grossi, R. Longo, G. Cerea, F. Rossetti

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Objective: The purpose of this study was to compare the costs of the drugs, drug administration and managing of adverse events (AEs) using erlotinib, docetaxel and pemetrexed as second line therapy in non-small cell lung cancer, in the Italian hospital setting. Methods: Since a clinical study comparing the three therapies is not available, the major clinical findings from randomized trials of each drug were used showing that all three chemotherapies have comparable efficacy results. Therefore a cost-minimization analysis was performed. Costs from the hospital perspective were calculated according to Italian clinical practice. Consumption of each chemotherapy was based on respective clinical trials, while to estimate the resources used in the AEs and for the drug administration a Delphi panel of experts was structured. In order to allow a comparison between an oral daily therapy (erlotinib) and infusion therapies administered every 21 days (docetaxel and pemetrexed), costs were computed on a monthly base. Results: The total per-patient cost for erlotinib was € 1,669, for docetaxel € 2,569 and for pemetrexed € 3,324 for one month therapy from the hospital perspective. Costs of AEs represent 8%, 18%, and 3% of the total costs for erlotinib, docetaxel, and pemetrexed, respectively. Sensitivity analysis showed that no reasonable changes in the quantity and cost of services reduced the savings associated with erlotinib by more than 33%. Conclusions: A cost-minimization analysis was performed to assess the costs of three second line chemotherapies in non-small cell lung cancer. The less costly alternative was erlotinib, which could produce savings between 40% and 50% of total hospital costs in Italy.

Original languageItalian
Pages (from-to)113-124
Number of pages12
JournalPharmacoEconomics - Italian Research Articles
Volume9
Issue number2
Publication statusPublished - 2007

Fingerprint

docetaxel
Pemetrexed
Non-Small Cell Lung Carcinoma
Cost-Benefit Analysis
Costs and Cost Analysis
Hospital Costs
Therapeutics
Drug Therapy
Drug Costs
Erlotinib Hydrochloride
Drug-Related Side Effects and Adverse Reactions
Pharmaceutical Preparations
Italy

ASJC Scopus subject areas

  • Pharmacology
  • Health Policy

Cite this

Valutazione economica di erlotinib, docetaxel e pemetrexed nel trattamento di seconda linea del carcinoma polmonare non a piccole cellule. / Capri, Stefano; Morabito, A.; Carillio, G.; Grossi, F.; Longo, R.; Cerea, G.; Rossetti, F.

In: PharmacoEconomics - Italian Research Articles, Vol. 9, No. 2, 2007, p. 113-124.

Research output: Contribution to journalArticle

@article{7ca2109951c1475e8bd430d2f590690a,
title = "Valutazione economica di erlotinib, docetaxel e pemetrexed nel trattamento di seconda linea del carcinoma polmonare non a piccole cellule",
abstract = "Objective: The purpose of this study was to compare the costs of the drugs, drug administration and managing of adverse events (AEs) using erlotinib, docetaxel and pemetrexed as second line therapy in non-small cell lung cancer, in the Italian hospital setting. Methods: Since a clinical study comparing the three therapies is not available, the major clinical findings from randomized trials of each drug were used showing that all three chemotherapies have comparable efficacy results. Therefore a cost-minimization analysis was performed. Costs from the hospital perspective were calculated according to Italian clinical practice. Consumption of each chemotherapy was based on respective clinical trials, while to estimate the resources used in the AEs and for the drug administration a Delphi panel of experts was structured. In order to allow a comparison between an oral daily therapy (erlotinib) and infusion therapies administered every 21 days (docetaxel and pemetrexed), costs were computed on a monthly base. Results: The total per-patient cost for erlotinib was € 1,669, for docetaxel € 2,569 and for pemetrexed € 3,324 for one month therapy from the hospital perspective. Costs of AEs represent 8{\%}, 18{\%}, and 3{\%} of the total costs for erlotinib, docetaxel, and pemetrexed, respectively. Sensitivity analysis showed that no reasonable changes in the quantity and cost of services reduced the savings associated with erlotinib by more than 33{\%}. Conclusions: A cost-minimization analysis was performed to assess the costs of three second line chemotherapies in non-small cell lung cancer. The less costly alternative was erlotinib, which could produce savings between 40{\%} and 50{\%} of total hospital costs in Italy.",
author = "Stefano Capri and A. Morabito and G. Carillio and F. Grossi and R. Longo and G. Cerea and F. Rossetti",
year = "2007",
language = "Italian",
volume = "9",
pages = "113--124",
journal = "PharmacoEconomics - Italian Research Articles",
issn = "1590-9158",
publisher = "Adis International Ltd",
number = "2",

}

TY - JOUR

T1 - Valutazione economica di erlotinib, docetaxel e pemetrexed nel trattamento di seconda linea del carcinoma polmonare non a piccole cellule

AU - Capri, Stefano

AU - Morabito, A.

AU - Carillio, G.

AU - Grossi, F.

AU - Longo, R.

AU - Cerea, G.

AU - Rossetti, F.

PY - 2007

Y1 - 2007

N2 - Objective: The purpose of this study was to compare the costs of the drugs, drug administration and managing of adverse events (AEs) using erlotinib, docetaxel and pemetrexed as second line therapy in non-small cell lung cancer, in the Italian hospital setting. Methods: Since a clinical study comparing the three therapies is not available, the major clinical findings from randomized trials of each drug were used showing that all three chemotherapies have comparable efficacy results. Therefore a cost-minimization analysis was performed. Costs from the hospital perspective were calculated according to Italian clinical practice. Consumption of each chemotherapy was based on respective clinical trials, while to estimate the resources used in the AEs and for the drug administration a Delphi panel of experts was structured. In order to allow a comparison between an oral daily therapy (erlotinib) and infusion therapies administered every 21 days (docetaxel and pemetrexed), costs were computed on a monthly base. Results: The total per-patient cost for erlotinib was € 1,669, for docetaxel € 2,569 and for pemetrexed € 3,324 for one month therapy from the hospital perspective. Costs of AEs represent 8%, 18%, and 3% of the total costs for erlotinib, docetaxel, and pemetrexed, respectively. Sensitivity analysis showed that no reasonable changes in the quantity and cost of services reduced the savings associated with erlotinib by more than 33%. Conclusions: A cost-minimization analysis was performed to assess the costs of three second line chemotherapies in non-small cell lung cancer. The less costly alternative was erlotinib, which could produce savings between 40% and 50% of total hospital costs in Italy.

AB - Objective: The purpose of this study was to compare the costs of the drugs, drug administration and managing of adverse events (AEs) using erlotinib, docetaxel and pemetrexed as second line therapy in non-small cell lung cancer, in the Italian hospital setting. Methods: Since a clinical study comparing the three therapies is not available, the major clinical findings from randomized trials of each drug were used showing that all three chemotherapies have comparable efficacy results. Therefore a cost-minimization analysis was performed. Costs from the hospital perspective were calculated according to Italian clinical practice. Consumption of each chemotherapy was based on respective clinical trials, while to estimate the resources used in the AEs and for the drug administration a Delphi panel of experts was structured. In order to allow a comparison between an oral daily therapy (erlotinib) and infusion therapies administered every 21 days (docetaxel and pemetrexed), costs were computed on a monthly base. Results: The total per-patient cost for erlotinib was € 1,669, for docetaxel € 2,569 and for pemetrexed € 3,324 for one month therapy from the hospital perspective. Costs of AEs represent 8%, 18%, and 3% of the total costs for erlotinib, docetaxel, and pemetrexed, respectively. Sensitivity analysis showed that no reasonable changes in the quantity and cost of services reduced the savings associated with erlotinib by more than 33%. Conclusions: A cost-minimization analysis was performed to assess the costs of three second line chemotherapies in non-small cell lung cancer. The less costly alternative was erlotinib, which could produce savings between 40% and 50% of total hospital costs in Italy.

UR - http://www.scopus.com/inward/record.url?scp=34748910727&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34748910727&partnerID=8YFLogxK

M3 - Articolo

AN - SCOPUS:34748910727

VL - 9

SP - 113

EP - 124

JO - PharmacoEconomics - Italian Research Articles

JF - PharmacoEconomics - Italian Research Articles

SN - 1590-9158

IS - 2

ER -